Harvard Bioscience, Inc.
HBIO
$0.4878
-$0.0028-0.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.41% | -16.14% | -13.15% | -11.36% | -6.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.41% | -16.14% | -13.15% | -11.36% | -6.76% |
| Cost of Revenue | -10.90% | -14.25% | -11.31% | -13.51% | -9.85% |
| Gross Profit | -16.87% | -17.45% | -14.39% | -9.78% | -4.47% |
| SG&A Expenses | -9.44% | -6.63% | -4.19% | -2.10% | -3.29% |
| Depreciation & Amortization | -7.09% | -4.89% | -6.64% | -9.48% | -9.50% |
| Other Operating Expenses | -97.52% | -- | -- | -- | -- |
| Total Operating Expenses | -11.44% | -9.50% | -6.31% | -6.49% | -5.44% |
| Operating Income | -195.69% | -307.94% | -252.25% | -341.67% | -6,868.18% |
| Income Before Tax | -602.98% | -356.38% | -469.64% | -45.67% | -764.47% |
| Income Tax Expenses | -84.30% | -13.85% | -3.81% | 219.64% | -54.34% |
| Earnings from Continuing Operations | -564.88% | -263.25% | -336.44% | -96.68% | -333.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -564.88% | -263.25% | -336.44% | -96.68% | -333.52% |
| EBIT | -195.69% | -307.94% | -252.25% | -341.67% | -6,868.18% |
| EBITDA | -54.79% | -79.26% | -76.63% | -65.14% | -25.60% |
| EPS Basic | -549.88% | -256.95% | -326.79% | -90.52% | -326.26% |
| Normalized Basic EPS | -33.79% | -406.67% | -2,844.90% | -94.22% | -112.17% |
| EPS Diluted | -542.34% | -238.04% | -302.30% | -87.81% | -292.56% |
| Normalized Diluted EPS | -34.66% | -405.29% | -2,729.41% | -93.39% | -115.01% |
| Average Basic Shares Outstanding | 2.16% | 2.53% | 2.33% | 2.42% | 2.39% |
| Average Diluted Shares Outstanding | 2.63% | 2.59% | 1.93% | 2.02% | 1.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |